Market scenario
Tularemia or rabbit fever or deer fly
fever is a rare infectious disease caused by the bacterium Francisella tularensis, which
affects skin, eyes, lymph nodes and lungs. Tularemia is transmitted from
animals such as rodents, rabbits, and hares to human. It can also affect sheep,
birds, dogs, cats, etc. The routes of acquiring infection are direct exposure
to the bacteria, airborne infections, insect bites, and bite of an infected animal.
Tularemia is highly contagious and had been used as a biological weapon by many
countries such as United States of America and Soviet Union. Ulceroglandular
tularemia is the most common form of Tularemia. Tularemia symptoms include
swollen and painful lymph glands, fever, chills, headache, fatigue, eye
swelling, pain and light sensitivity, diarrhea, pneumonia etc. If it left
untreated, it will cause serious complications such as enlarged spleen,
enlarged liver, infection around the brain and spinal cord,
irritation around the heart (pericarditis), bone infection etc. and may lead to
the death.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4120
Factors favouring the spread of
Tularemia infection are tick bites, exposure to sick or dead animals,
especially, wild game. Travel to certain regions such as Arkansas, Missouri and
Oklahoma can also cause Tularemia infection because of the concentration of
ticks in those areas. Tick bite is the leading cause for an occurrence of large
number of cases.Laboratory workers working with tularemia are at risk of
airborne infection due to greater chances of exposure to the pathogen.
Tularemia infection can also be airborne during gardening, construction or
other activities, which may lead to pneumonic tularemia. Tularemia is also
contracted by eating undercooked meat of an infected animal or drinking
contaminated water. According to Centers for Disease Control and Prevention,
overall mortality of Tularemia is less than 2% but ranges up to 24% depending
on the strain.
The global Tularemia treatment market is expected to
reach US$ 200 million by 2023, and the market is projected to grow at a CAGR of
~ 3.2 % during the forecast period 2017-2023.
Sources: U.S. Department of Health and
Human Services National Institutes of Health, Centers for Disease Control and
Prevention, Mayo Clinic, MRFR Analysis
Intended Audience
- Global Tularemia manufacturers & suppliers
- Research and development (R&D) companies
- Hospitals and clinics
- Academic institutes and universities
Segments
The global Tularemia market has been
segmented on the basis of types, diagnosis, drugs, and end users.
Based on types, the market has been
segmented as the ulceroglandular tularemia, glandular tularemia, oculoglandular
tularemia, oropharyngeal tularemia, pneumonic tularemia, and others.
Based on the diagnosis, the market has
been segmented as microscopy, immunochemistry, and others.
Based on the drugs, the market has been
segmented as streptomycin, gentamicin, doxycycline, ciprofloxacin and others.
Based on the end users, the market has
been segmented as hospitals and clinics, academic and research centers, and
others.
Regional analysis
The Americas accounts for the
significant market share owing to extensive use of medications and high
expenditure on the health care. Additionally, the fastest uptake of new
technology and drugs in the US drives the global Tularemia market. However the
presence and concentration of Tularemia in the US regions, for
instance, Arkansas, Missouri, Dakota, Oklahoma, etc. are the leading cause
for the dominance of US in the global Tularemia market. Europe is the
second largest market in the globe due to a high disposable income and rising
awareness about the disease.
Asia Pacific region is expected to grow
rapidly and China and India are likely to lead the market due to unmet needs
during the forecast period.
Gulf nations such as Saudi Arabia and
the UAE drive the Middle East & African market. The African region is
expected to witness a moderate growth owing to poor economic and political
conditions and poor healthcare development. However Africa is also a region of
high endemic and untreated cases of Tularemia.
Key Players in the Global Tularemia Market
Some of key players profiled in the
report are Nicholas Piramal, Alkem, Glaxo Smithkline, Bayer AG, Ranbaxy
Laboratories, Cipla Inc., Zydus Cadila, Dr. Reddy's Lab, Glenmark
Pharmaceuticals, Lupin Limited, pfizer Inc. and others.
The report for Global Tularemia
market by Market Research Future comprises of extensive primary
research along with the detailed analysis of qualitative as well as
quantitative aspects by various industry experts, key opinion leaders to gain a
deeper insight of the market and industry performance. The report gives a clear
picture of the current market scenario which includes past and estimated future
market size with respect to value and volume, technological advancement, macro
economical and governing factors in the market. The report provides detail
information about and strategies used by top key players in the industry. The report
also gives a broad study of the different market segments and regions.
FOR MORE DETAILS
– https://www.marketresearchfuture.com/reports/tularemia-market-4120
No comments:
Post a Comment